register

News & Trends - Pharmaceuticals

Sanofi’s second brand of insulin glargine on the PBS

Health Industry Hub | July 29, 2020 |

Pharma News: Sanofi’s Lantus (Insulin glargine U100) is a vital treatment for patients with type 1 and type 2 diabetes.

Changes have been made from 1 July 2020 to the PBS listings for insulin glargine, as the brands Lantus and Lantus SoloStar are no longer available on the PBS.

Lantus was delisted due to biosimilar insulins arriving in Australia. Alphapharm’s Semglee was listed on the PBS in October 2019. It is not the first biosimilar insulin glargine on the Australian market. Back in 2015, Abasria was approved by the TGA which marketed by Eli Lilly and available as a private script only.

Sanofi’s OPTISULIN is the same formulation as Lantus and is available in the same familiar presentations and devices, including the SoloStar pre-filled device and cartridges for use in either AllStar Pro and JuniorStar reusable pens. It requires no dose adjustment when transitioning from Lantus and patients transitioning to OPTISULIN should continue to administer their dose at the same time of the day and monitor their blood glucose levels as directed by their treating clinician.

There is also the option for clinicians to move patient to a second generation basal insulin. Sanofi’s Toujeo (insulin glargine U300 or GLA-300) may be a an alternate option to consider with a simple initiation regimen and a reduced risk of hypoglycaemia.


News & Trends - Pharmaceuticals

Clinicians unveil Novartis and BMS practice-changing trial results

Clinicians unveil Novartis and BMS practice-changing trial results

Health Industry Hub | June 24, 2024 |

Pharma News: Australia, known for its alarming melanoma rates, witnesses one person diagnosed with the disease every 30 minutes, and […]

More


News & Trends - Pharmaceuticals

Hearts4heart leads awareness week, amid progress in Boehringer Ingelheim and AstraZeneca therapies

Hearts4heart leads awareness week, amid progress in Boehringer Ingelheim and AstraZeneca therapies

Health Industry Hub | June 24, 2024 |

Pharma News: Heart failure is a significant health concern in Australia, affecting approximately half a million people, with over 67,000 […]

More


News & Trends - MedTech & Diagnostics

Cardiologists mark Australian first with Boston Scientific's intracoronary imaging system

Cardiologists mark Australian first with Boston Scientific’s intracoronary imaging system

Health Industry Hub | June 24, 2024 |

MedTech & Diagnostics News: Percutaneous coronary intervention (PCI) has faced substantial complications and failure rates, despite advances in medical devices […]

More


Leadership & Management

AbbVie New Zealand welcomes new leadership amid global moves

AbbVie New Zealand welcomes new leadership amid global moves

Health Industry Hub | June 24, 2024 |

Leadership & Management: In line with its global talent development plan, AbbVie has announced a significant change in leadership for […]

More


This content is copyright protected. Please subscribe to gain access.